特瑞普利单抗、卡培他滨与放疗三联方案治疗中晚期鼻咽癌的临床价值探讨
Exploration of the Clinical Value of the Triple Therapy of Trastuzumab, Capecitabine, and Radiotherapy in the Treatment of Advanced Nasopharyngeal Carcinoma

目的：分析特瑞普利单抗、卡培他滨与放疗三联方案治疗中晚期鼻咽癌的效果。方法：入选样本是60例中晚期鼻咽癌患者，信封法分成两组，各30例，普通组采取卡培他滨与放疗方案，调查组采取特瑞普利单抗、卡培他滨与放疗方案，于2023年1月~2024年4月期间调查，分析不同治疗方案下的疗效、患者肿瘤标志物水平差异、免疫功能差异，观察其不良反应及远期疗效。结果：治疗有效数据相比，调查组 > 普通组，即93.33% (28例) VS 73.33% (22例)，P < 0.05；肿瘤标志物水平相比，治疗前组间无差异(P > 0.05)，治疗后调查组水平均 < 普通组水平，P < 0.05；组间免疫功能指标相比，治疗前数据水平无显著差异，P > 0.05，治疗后调查组均优于普通组，P < 0.05；组间不良反应水平高，且数据显著差异，P > 0.05，但调查组复发率 < 普通组复发率，P < 0.05。结论：特瑞普利单抗、卡培他滨与放疗三联方案治疗中晚期鼻咽疗效确切，并降低肿瘤标志物水平，且对机体免疫影响较小，该方案具有较好的预后，可减少复发，但治疗期间需要对不良反应的发生和控制引起重视。
Objective: To analyze the efficacy of the triple therapy of trastuzumab, capecitabine, and radiotherapy in the treatment of advanced nasopharyngeal carcinoma. Method: The selected sample consisted of 60 patients with advanced nasopharyngeal carcinoma. They were divided into two groups using the envelope method, with 30 patients in each group. The control group received capecitabine and radiation therapy, while the investigation group received trastuzumab, capecitabine, and radiation therapy. The study was conducted from January 2023 to April 2024 to analyze the efficacy, differences in patient tumor marker levels, and differences in immune function under different treatment regimens, and to observe their adverse reactions and long-term efficacy. Results: Compared with the control group, the effective treatment data was higher in the survey group, with 93.33% (28 cases) vs 73.33% (22 cases), P < 0.05; Compared with the level of tumor markers, there was no difference between the groups before treatment (P > 0.05). After treatment, the average water level of the investigation group was lower than that of the ordinary group, P < 0.05; Compared with the immune function indicators between groups, there was no significant difference in the data level before treatment, P > 0.05. After treatment, the investigation group was better than the ordinary group, P < 0.05; The level of adverse reactions between groups is high and there is a significant difference in data, P > 0.05, but the recurrence rate of the survey group is lower than that of the general group, P < 0.05. Conclusion: The triple therapy of trastuzumab, capecitabine, and radiotherapy has a definite therapeutic effect on advanced nasopharyngeal carcinoma, reduces tumor marker levels, and has a small impact on the body’s immune system.